Incyte assumed with an Overweight at Piper Jaffray. Piper Jaffray analyst Tyler Van Buren assumed coverage of Incyte (INCY) with an Overweight rating and $85 price target, stating that he expects Jakafi to produce durable, high-margin revenues approaching $2.5-$3B over the next ten years and predicts Incyte and partner Lilly (LLY) will receive an approval for baricitinib next week.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.